💥 The end of Pembro reign? Phase 3 Study of Ivonescimab (AK112) vs. Pembrolizumab as First-line Treatment for PD-L1-positive Advanced NSCLC: HARMONi-2 #WCLC24 #LCSM

BLU-945, a next-gen EGFR TKI, shows promise against osimertinib-resistant NSCLC, shrinking tumors in preclinical models and in patients from the SYMPHONY trial. This could help fill treatment gaps for EGFR-mutant lung cancer. Read more: doi.org/10.1177/175883…

Neoadjuvant ipilimumab + nivolumab in resectable stage III melanoma shows superior 12-mo EFS (83.7%) vs adjuvant alone (57.2%)! 🔬Major pathological response in 59%. Grade 3+ AEs: 29.7% vs 14.7%. #Melanoma #Immunotherapy #Oncology OncoAlert NEJM nejm.org/doi/full/10.10…

📣 NUEVA FORMACIÓN: El próximo lunes 11 noviembre celebramos el Webinar #CáncerdePulmón MAP (Programa de Ayuda MDT) - Fase II, que cuenta con la colaboración de AstraZeneca España. 💻 Sesión virtual 👉 Acceso a inscripción y programa: saom.es/congresos-curs… 🚀 ¡No te la pierdas!

Trastuzumab Deruxtecan in Advanced Solid Tumors With HER 2 Amplification Identified by cfDNA Journal of Clinical Oncology doi.org/10.1200/JCO.23… 🔎HERALD/EPOC1806 phs II Basket, 61 pts, 16 tumor types 👉 ORR 56%, PFS 7.0 mo, DoR 8.8 mo, mOS 14.6 mo 🧐cfDNA useful to identify HER2 amplified tumors

#NewProfilePic

To understand #autoimmunity, you have to first understand #immunity. James Lillard walks through the different types of immunity and their role in the immune response. Check out #ImmunologyExplained to learn more: bit.ly/3XZgflj.

Hey American Association of Peruvian Physicians (AAPP), let’s keep an eye on things and see if this shifts the direction for the new exam takers.

Over the last 50 years, 101 million infants around the world were saved by vaccines. Elevating anti-vaccine conspiracy theories would cost lives. Morning Joe

Epigenetics-targeted drugs: current paradigms and future challenges Many drugs are being developed in every field of oncology👇 nature.com/articles/s4139…

Happy Thanksgiving with the most impressive KM curve you’ll see today. PFS for first line nivo/ipi vs chemo in MSI-H mCRC. 🛻 Truck test: <0.001 nejm.org/doi/full/10.10…

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer 2y PFS➡️72% vs 14% 💥When the right drug is given to the right patient at the right time, the survival curves can be as perfect as the one below👇 nejm.org/doi/full/10.10…

After we reach advanced age, around 80, the propensity to develop cancer is markedly reduced. A discovery reported nature today about aged stem cells and iron insufficiency may help explain this advantage nature.com/articles/d4158… Nature News & Views nature.com/articles/s4158…

Today we officially welcome our new residents and fellows to TidalHealth! We're excited to have you on site and look forward to supporting you throughout your training journey. Wishing each of you a successful, rewarding year ahead!